|
|
|
|
|
|
|
|
|
06.08.26 - 22:06
|
Prothena Reports Second Quarter 2026 Financial Results and Business Highlights (Business Wire)
|
|
|
Net cash used in operating and investing activities was $25.7 million in the second quarter and net cash provided by operating and investing activities was $3.2 million for the first six months of 2026; quarter-end cash and restricted cash position was $289.1 million
Guidance updated to include shares repurchased through July 30, 2026 and now expects to end the year with approximately $259 million (midpoint) in cash, cash equivalents and restricted cash
Results from partner Roche evaluating prasinezumab in patients with early Parkinson's disease from the Phase 2b PADOVA clinical trial published in The Lancet
Multiple research collaborations with industry partners ongoing to explore the potential of our CYTOPE® technology over the next 12 to 24 months
DUBLIN--(BUSINESS WIRE)--$PRTA #Prothena--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results f...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31.07.26 - 14:00
|
Moog Inc. Achieves Record Third Quarter 2026 Results Through Operational Excellence and Raises Full-Year Guidance (Business Wire)
|
|
|
EAST AURORA, N.Y.--(BUSINESS WIRE)--Moog Inc. (NYSE: MOG.A and MOG.B), a worldwide designer, manufacturer and systems integrator of high-performance precision motion and fluid controls and control systems, today reported fiscal third quarter 2026 results, reflecting record sales and adjusted earnings per share, expanded operating margin and strong cash generation.
“These third quarter results demonstrate the strength of Moog's portfolio and operational excellence,” said Pat Roche, CEO. “We are clear about where we win, disciplined on how we work, selective about where we invest, and able to turn attractive market demand into improved financial performance.”
(in millions, except per share results)
Three Months Ended
Q3 2026
Q3 2025(2)
Deltas
Net sales
$
1,117
$
970
15
%
Operating margin
15.8
%
11.5
%
430 bps
Adjusted operating margin(1)
16.4
%
13.6
%
280 bps
Net earnings
$
152
$
58
160
%
Adjusted net earnings(1)
$
119
$
74
?...
|
|
|
|
|
28.07.26 - 15:39
|
Roche Aktie: Starke Pipeline, begrenztes Kurspotenzial (Aktiencheck)
|
|
|
Wien (www.aktiencheck.de) - Roche-Aktienanalyse von der Raiffeisen Bank International AG:
Julian Lindinger, Analyst der Raiffeisen Bank International AG (RBI), stuft die Aktie der Roche Holding AG (ISIN: CH0012032113, WKN: 851311, Ticker-Symbol: RHO, SIX Swiss Exchange-Symbol: RO, NASDAQ OTC-Symbol: RHHBF) von KAUF auf HALTEN herunter. [mehr]...
|
|
|
28.07.26 - 13:03
|
Newleos Names Rohan Palekar as Board Chairman (Business Wire)
|
|
|
– Prominent biotech leader and former Chief Executive Officer of 89bio joins Newleos Board of Directors –BOSTON--(BUSINESS WIRE)--#AnxietyDisorders--Newleos Therapeutics, Inc., a clinical-stage biotechnology company developing innovative treatments for neuropsychiatric disorders, today announced the appointment of Rohan Palekar to its Board of Directors. Most recently, Mr. Palekar served as founding Chief Executive Officer at 89bio where he led multiple programs from preclinical studies through Phase 3 development in liver and cardiometabolic diseases. 89bio was acquired by Roche in 2025 for up to $3.5 billion.
In connection with his appointment, Mr. Palekar was elected Chairman of the Newleos Board. Christoph Westphal, M.D., Ph.D., who has served as Newleos' Executive Chairman since the company's founding, will step down from the role but will continue to serve on the Newleos Board on behalf of founding investor Longwood Fund.
“I am honored to join the Newleos Board as the company approaches key ...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
